---
title: "PMV Pharmaceuticals Adds Veteran Investor to Board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300939400.md"
description: "PMV Pharmaceuticals appointed Matt Eckler, a veteran healthcare investor and scientist, to its board of directors on October 1, 2026. This move aims to support the company's push toward commercialization of rezatapopt for ovarian cancer as it prepares a New Drug Application following Phase 2 trial enrollment completion. While analyst ratings suggest a Buy with a $5 target, TipRanks' AI tool rates PMVP as Neutral due to weak financials despite constructive technicals and recent corporate developments."
datetime: "2026-10-05T13:29:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300939400.md)
  - [en](https://longbridge.com/en/news/300939400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300939400.md)
generator: "portal-rs"
---

# PMV Pharmaceuticals Adds Veteran Investor to Board

PMV Pharmaceuticals ( (PMVP) ) has issued an update.

On October 1, 2026, PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a veteran healthcare investor and scientist, to its board of directors for a term running through the 2029 annual meeting of stockholders. Eckler, currently a Principal at Samsara BioCapital and formerly an investment professional at firms including ArrowMark Partners and GMT Capital, will receive standard cash and equity compensation under PMV’s outside director policy.

His appointment, announced publicly on October 5, 2026, comes as PMV completes enrollment in the Phase 2 monotherapy portion of its PYNNACLE pivotal trial and prepares a planned New Drug Application for rezatapopt in platinum-resistant or refractory ovarian cancer with a TP53 Y220C mutation. Rezatapopt, a first-in-class p53 reactivator, already holds U.S. Fast Track and Orphan Drug designations, and Eckler’s capital markets and scientific background is expected to support PMV’s push toward potential commercialization and its broader growth ambitions in precision oncology.

The most recent analyst rating on (PMVP) stock is a Buy  
 with a $5.00 price target.  
 To see the full list of analyst forecasts on PMV Pharmaceuticals stock,  
 see the PMVP Stock Forecast page. 

**Spark’s Take on PMVP Stock**

According to Spark, TipRanks’ AI Analyst, PMVP is a Neutral.

The score is held back primarily by weak financial performance: no revenue, substantial operating losses, and significant ongoing cash burn. Offsetting this, technicals are constructive (price above major moving averages with positive MACD), and recent corporate events are supportive with strong Phase 2 results and financing that extends runway into Q1 2028. Valuation remains difficult to assess due to negative earnings and no dividend yield data.

To see Spark’s full report on PMVP stock,  
 click here. 

**More about PMV Pharmaceuticals**

PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies targeting p53, a tumor-suppressor protein with TP53 mutations present in about half of all cancers. Founded on more than four decades of p53 biology and headquartered in Princeton, N.J., PMV Pharma is advancing candidates such as rezatapopt for difficult-to-treat solid tumors.

The company leverages its deep scientific expertise and pharmaceutical development capabilities to pursue targeted treatments for patients with TP53-mutated cancers, including ovarian, fallopian tube, and primary peritoneal cancers. Its work is supported by U.S. regulatory designations such as Fast Track and Orphan Drug status for rezatapopt in defined TP53 Y220C-positive indications.

**Average Trading Volume:** 629,399

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $135.2M

Learn more about PMVP stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [PMVP.US](https://longbridge.com/en/quote/PMVP.US.md)

## Related News & Research

- [BUZZ-Oncology firm PMV Pharma falls on $51 mln stock-and-warrants sale](https://longbridge.com/en/news/297642898.md)
- [PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push](https://longbridge.com/en/news/297657742.md)
- [TSMC Q3 Earnings Preview: Can Profit Hit a Record High for a Sixth Straight Quarter? Wall Street's Highest Target Price Is $665](https://longbridge.com/en/news/301683133.md)
- [Faraday Future shifts to robotaxi sharing network, AI VisiCabin operator model](https://longbridge.com/en/news/301835634.md)
- [Nvidia Is Using Its Cash to Build the Next Generation of AI Customers](https://longbridge.com/en/news/301758383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**